Peptide-receptor radionuclide therapy for endocrine tumors.
about
Synthetic nanoparticles for delivery of radioisotopes and radiosensitizers in cancer therapyInsights into bombesin receptors and ligands: Highlighting recent advancesNeuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upBombesin analogue-mediated delivery preferentially enhances the cytotoxicity of a mitochondria-disrupting peptide in tumor cellsMedical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR)Molecular optical imaging with radioactive probes.Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel.Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients.Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analogBombesin receptor-mediated imaging and cytotoxicity: review and current statusSomatostatin Receptors in Lung Cancer: From Function to Molecular Imaging and TherapeuticsDisclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imagingSomatostatin receptor based imaging and radionuclide therapy.Measured human dosimetry of 68Ga-DOTATATE.A multimodal approach to the management of neuroendocrine tumour liver metastasesManagement of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.Molecular theranostics: a primer for the imaging professionalThree-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy.Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances(68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity.Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues.Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms.Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours.Radiometallated peptides targeting guanylate cyclase C and the urokinase-type plasminogen activator receptor.Radiometallated peptides for molecular imaging and targeted therapy.The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant.Emerging therapeutic options for advanced enteropancreatic neuroendocrine tumors.Radiolabelled RGD peptides for imaging and therapy.Radionuclide therapy via SSTR: future aspects from experimental animal studies.Radionuclide therapy of adrenal tumors.The role of preclinical SPECT in oncological and neurological research in combination with either CT or MRI.(177)Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model.Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour.Selective internal radiation therapy for gastrointestinal neuroendocrine tumour liver metastases: a new and effective modality for treatment.177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi.Production and dosimetric aspects of the potent Auger emitter 58mCo for targeted radionuclide therapy of small tumors.Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.Peptide receptor radionuclide therapy (PRRT) with [(177)Lu-DOTA(0),Tyr(3)]octreotate in combination with RAD001 treatment: further investigations on tumor metastasis and response in the rat pancreatic CA20948 tumor model.Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors.
P2860
Q28066010-F78107AA-78DA-4645-A8A9-48436A1C0FC2Q28081153-B8B10278-AF66-442F-B9AA-D4EADC210F4AQ28285545-1879659A-1556-401F-B132-135A901D0DBDQ28486692-50B63BF2-4AAE-4EAA-833A-53CF1ECBDEBAQ28651176-F786A38B-E4C6-4ABA-A8B8-135E1D4258F2Q30979164-C0891123-BEA9-440F-8788-D720DC451F6AQ33782024-93838162-9D43-41A6-9DD8-06A2A6ACF09BQ33849461-A80FB7FC-82E8-4579-BD39-2CB241A805CBQ34514544-A9B67BD5-178E-4934-A1F9-454712D7157BQ34684387-28CC336F-F7E8-4E25-BCFB-3EE520C680D9Q35057473-002C9E0A-E9CD-4979-8779-5686E72E3C7CQ35227508-E4B85A04-0EF8-4B44-B0BC-7A9EBB5A88F9Q35296661-D6549B24-FDEF-4F39-A8E4-97CB71233922Q35756123-293021E8-78D4-4784-BAD2-D5347710B457Q35810562-8B5FB85C-6AD4-4112-8689-BF19E9D85B95Q36184629-BED4B6DA-31E2-4C54-8C8E-1D45FF41A746Q36251545-960E49F5-35A8-49BA-8F63-60ED21643A9AQ36300599-5259AACF-BE86-4D1E-A4EA-3BD2DE2158CAQ37125550-714DA424-479A-4333-BD88-962E0F3D6CD0Q37185143-8731C54D-AD5A-40C4-8C5F-C38298C92D6CQ37323454-93604FA2-788D-4250-ADDA-43AF39443029Q37720857-E629ED5D-1F2C-41C8-B600-B41E2AF7D5BCQ37731335-83785F26-2297-417B-8826-0FAB11549362Q37765569-495D5818-4300-4865-99B1-18EFFD96B419Q37783622-2BD2655A-7D4D-4C65-8941-7FBEB02DDC8BQ37847064-8BA06C61-24D4-48E4-82A2-A9DC13B27BAAQ37869391-96FC61E5-C07C-4485-B858-D99269D97307Q37980202-A76FC6A8-42F7-48E3-BA45-AF049E51F03EQ37990409-4DD52D1F-5CE3-4475-962B-F5A8E4635D7EQ38008839-63C95B38-2D6F-47D2-9DBE-082D355AF0FCQ38020428-D456C2AD-EDF0-465D-81D9-9BB79A04BCF0Q38217493-890C3FF9-81DA-455B-A240-E0F7766F7B93Q38853973-D1A511A5-D431-441E-9EA0-F9C84E0C560DQ39267922-9DF4838E-0DC2-4A10-91FA-50953D59FB71Q39491049-5B23A47C-3E48-4F8D-A6FC-4B1D87D90D37Q39632700-F8D07DCE-7F9F-45DF-918A-4D23C31969E9Q39706347-9AF2DBCD-7244-45B8-AD11-6BC7F2E30AD5Q40676597-E9DEC296-F02B-4365-AAA0-2510A62CEB0FQ41143314-DD346FBC-A9DA-4C34-82B3-26FBB6142E16Q41244010-AC8CDB34-E432-4A10-8410-E0FB0CCED6F3
P2860
Peptide-receptor radionuclide therapy for endocrine tumors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Peptide-receptor radionuclide therapy for endocrine tumors.
@en
Peptide-receptor radionuclide therapy for endocrine tumors.
@nl
type
label
Peptide-receptor radionuclide therapy for endocrine tumors.
@en
Peptide-receptor radionuclide therapy for endocrine tumors.
@nl
prefLabel
Peptide-receptor radionuclide therapy for endocrine tumors.
@en
Peptide-receptor radionuclide therapy for endocrine tumors.
@nl
P2093
P2860
P356
P1476
Peptide-receptor radionuclide therapy for endocrine tumors.
@en
P2093
Boen L R Kam
Dik J Kwekkeboom
Eric P Krenning
Marion de Jong
Martijn van Essen
Roelf Valkema
P2860
P2888
P304
P356
10.1038/NRENDO.2009.105
P577
2009-06-02T00:00:00Z